Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors

Thomas F. Rogers(Scripps Research Institute), Eileen C. Goodwin(Adimab (United States)), Bryan Briney(Scripps Research Institute), Devin Sok(Scripps Research Institute), Nathan Beutler(Scripps Research Institute), Alexander Strubel(Scripps Research Institute), Rebecca Nedellec(Scripps Research Institute), Khoa Le(Scripps Research Institute), Michael E. Brown(Adimab (United States)), Dennis R. Burton(Scripps Research Institute), Laura M. Walker(Adimab (United States))
Science Immunology
August 4, 2017
Cited by 97Open Access
Full Text

Abstract

Zika virus (ZIKV) shares a high degree of homology with dengue virus (DENV), suggesting that preexisting immunity to DENV could affect immune responses to ZIKV. We have tracked the evolution of ZIKV-induced B cell responses in three DENV-experienced donors. The acute antibody (plasmablast) responses were characterized by relatively high somatic hypermutation and a bias toward DENV binding and neutralization, implying the early activation of DENV clones. A DENV-naïve donor in contrast showed a classical primary plasmablast response. Five months after infection, the DENV-experienced donors developed potent type-specific ZIKV neutralizing antibody responses in addition to DENV cross-reactive responses. Because cross-reactive responses were poorly neutralizing and associated with enhanced ZIKV infection in vitro, preexisting DENV immunity could negatively affect protective antibody responses to ZIKV. The observed effects are epitope-dependent, suggesting that a ZIKV vaccine should be carefully designed for DENV-seropositive populations.


Related Papers

No related papers found

Powered by citation graph analysis